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Repeated injection of opioid analgesics can lead to a progressive loss of effect. This phenomenon 
is known as tolerance. Several lines of investigations have shown that systemic, intraperitoneal 
administration or the microinjection of non-opioid analgesics, non-steroidal anti-inflammatory 
drugs (NSAIDs) into the midbrain periaqueductal gray matter induces antinociception with 
some effects of tolerance. Our recent study has revealed that microinjection of three drugs 
analgin, ketorolac, and xefocam into the central nucleus of amygdala produce tolerance to 
them and cross-tolerance to morphine. Here we report that repeated administrations of these 
NSAIDs into the nucleus raphe magnus (NRM) in the following 4 days result in progressively 
less antinociception compare to the saline control, i.e., tolerance develops to these drugs in 
male rats. Special control experiments showed that post-treatment with the μ-opioid antagonist 
naloxone into the NRM significantly decreased antinociceptive effects of NSAIDs on the first 
day of testing in the tail-flick (TF) reflex and hot plate (HP) latency tests. On the second day, 
naloxone generally had trend effects in both TF and HP tests and impeded the development of 
tolerance to the antinociceptive effect of non-opioid analgesics. These findings strongly support 
the suggestion of endogenous opioid involvement in NSAIDs antinociception and tolerance in 
the descending pain-control system. Moreover, repeated injections of NSAIDs progressively 
lead to tolerance to them, cross-tolerance to morphine, and the risk of a withdrawal syndrome. 
Therefore, these results are important for human medicine too.
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1996). Moreover, repeated microinjections of dipyrone and lysine-
acetylsalicylate (LASA) into the PAG produced opioid like toler-
ance in rats, together with a withdrawal syndrome (Tortorici and 
Vanegas, 2000; Pernia-Andrade et al., 2004; Tortorici et al., 2004, 
2009). Our recent findings also have shown the same effects of tol-
erance following intraperitoneal (i.p.) injections of analgin (meta-
mizol), ketorolac, and xefocam (Tsagareli et al., 2005; Tsiklauri and 
Tsagareli, 2006; Tsiklauri et al., 2006, 2008; Tsiklauri et al., 2010). 
Taken together these studies support the notion that contribution 
of the downstream pain-control system to the tolerance effects of 
the above-mentioned NSAIDs involves endogenous opioidergic 
mechanisms (Hernández-Delgadillo and Cruz, 2006; Henricher 
and Ingram, 2009; Vanegas et al., 2010). Just recently, we have shown 
that microinjection of three NSAIDs analgin, ketorolac, and xefo-
cam into the central nucleus of amygdala (CeA) produced tolerance 
to these drugs and cross-tolerance to morphine (Tsagareli et al., 
2009, 2010).
In the present study, we have examined whether microinjection 
of analgin (metamizol), clodifen, ketorolac, and xefocam into the 
NRM leads to the development of tolerance and whether their 
action in the NRM is opioid sensitive.
Materials and Methods
aniMals
The experiments were carried out on male Wistar rats (200–250 g) 
bred at the Beritashvili Institute of Physiology. The experimen-
tal protocol was approved by the local Bioethic Committee of the 
introduction
It has been established that the pain-control system includes the 
midbrain periaqueductal gray matter (PAG) and rostral ventro-
medial medulla (RVM). The RVM involves the midline nucleus 
raphe magnus (NRM) and adjacent reticular formation. The med-
ullar NRM is one of the important parts of the CNS circuit that 
controls nociceptive transmission at the level of the spinal cord. It 
is functionally involved in descending pain modulation, and mainly 
consists of serotoninergic neurons (Fields, 2004; Fields et al., 2006; 
Ren and Dubner, 2009). The PAG controls nociceptive transmission 
mainly through the RVM. The PAG–RVM system is the central 
substrate for the actions of opioid analgesic drugs. Endogenous 
opioid peptides are present in neural somata and/or terminal fields 
in several components of this network. In animals, electrical stimu-
lation of the PAG inhibits simple noxious-stimulus reflexes, such 
as seen in the tail-flick (TF) and/or hot plate (HP) paw withdrawal 
tests. Furthermore, this circuit contributes to opiate analgesia and 
opioid dependence (Henricher and Ingram, 2009; Heinricher et al., 
2009; Ren and Dubner, 2009).
Several lines of investigations have shown that in the PAG and 
RVM, the microinjection of non-opioid analgesics, and non-ste-
roidal anti-inflammatory drugs (NSAIDs) induces antinocicep-
tion but with some evidence of tolerance (Jones, 1996; Tortorici 
and Vanegas, 2000; Pernia-Andrade et al., 2004; Tortorici et al., 
2004, 2009). Specifically, microinjections of dipyrone (metami-
zol) into the medullary NRM of lightly pentobarbital-anesthetized 
rats dose-dependently inhibited the nociceptive TF reflex (Jones, 
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(Sigma Chemical, Co.), and the animal was killed with ester by 
an overdose of an anesthetic. After fixation by immersion in 10% 
formalin the brain was sectioned and the microinjection site was 
identified with the aid of Paxinos and Watson (1997) stereotaxic 
atlas coordinates.
statistical analysis
All data are presented as mean ± SEM. Analysis of variance (ANOVA) 
with post hoc Tukey–Kramer Multiple Compayon Tests were used 
for statistical evaluations of comparisons between treated and 
saline groups, and treated and naloxone groups respectively. The 
Kolmogorov–Smirnov test was applied to verify normality. The sta-
tistical software utilized was InStat 3.05 (GraphPad Software, Inc., 
USA). Statistical significance between vehicle control and treated 
groups, and naloxone and treated groups of rats was acknowledged 
if P < 0.05.
results
histology control
Only rats with microinjections located in the NRM were included 
for data analysis. Histological location of microinjection sites is 
shown in a simplified drawing section from the Paxinos and Watson 
(1997) atlas. All microinjections of NSAIDs or saline were histologi-
cally located in the NRM (Figure 1).
Institute and Guidelines of the International Association for the 
Study of Pain regarding animal experimentation were followed 
throughout (Zimmermann, 1983).
surgical procedures
Under anesthesia with thiopental (55 mg/kg, i.p. “Kievmed” 
Ukraine) a 12-mm-long stainless steel guide cannula (Small 
Parts, Inc., USA) was stereotaxically implanted (AP: −9.16; L: +1; 
H: 9.8) according to the coordinates in the atlas of Paxinos and 
Watson (1997) siting the tip 2 mm above the NRM. The guides 
were anchored to the cranium by dental cement. The guide cannula 
was plugged with a stainless steel stylet. Thereafter, the rats were 
handled every day for 3 days for 15 min to get familiar with the 
testing protocol and experimental environment. During this time, 
the stylet was removed and 14 mm-long stainless steel microin-
jection cannula was inserted into the guide cannula to reach the 
NRM, but no drug was injected. This helped to habituate the rats 
to the injection procedure and to reduce artifacts arising from 
mechanical manipulation during the test days. Five days after 
surgery the microinjection cannula, attached to a 5-μl Hamilton 
syringe (Hamilton, Inc., USA), was joined to the guide cannula, 
and the drug was introduced through it while the rat was gently 
restrained.
drugs
Analgin 150 μg/0.5 μl (metamizol sodium, “Sanitas,” Ltd., 
Lithuania), clodifen (diclofenac sodium, 75 μg/0.5 μl, “E.I.P.I.” 
Comp., Egypt), ketorolac (ketorolac tromethamine, 90 μg/0.5 μl, 
“Zee Drugs,” India), xefocam (lornoxicam, 12 μg/0.5 μl, “Nycomed,” 
GmbH, Austria) were then injected through the microinjec-
tion cannula; then the guide cannula was plugged with a stain-
less steel stylet. Saline was injected in the same volume (0.5 μl; 
“GalichPharm” Ltd., Ukraine) and manner in a separate group 
of rats for controls.
Behavioral testing
Twenty minutes post microinjection, i.e., 10-min before the peak of 
the drugs’ effect is normally reached, animals were tested with TF or 
HP. For the TF test, the distal part of the tail was stimulated with a 
light beam (IITC #33, IITC Life science, Inc., Woodland Hills, CA, 
USA) and the latency measured until the tail was reflexively flicked 
away from the beam. For the HP test, the rat was placed on a 55°C 
HP (IITC #39) and the latency to the first lick of the hindpaw or 
jumping was measured. The cut-off time was 20 s for both TF and 
HP latencies. Each rat was tested for both TF and HP latencies in 
the same session. A similar procedure was followed for the repeated 
microinjection of analgine, clodifen, ketorolac, xefocam, or saline 
for five consecutive days.
In a separate set of experiments, 20 min following NSAIDs 
administration we tested whether post-treatment with the μ-opioid 
antagonist naloxone (0.5 μl) in the NRM diminishes NSAID-
induced antinociception on the first and second experimental days.
histology
At the end of each experiment, after the fifth day and the second 
day of the second series of experiments the microinjection site was 
marked with 2 μl of a saturated solution of Pontamine Sky Blue 
Figure 1 | Histologically verified microinjection sites for analgin, 
clodifen, ketorolac, xefocam, or saline in the NrM, in transverse sections 
simplified from Paxinos and Watson (1997) atlas. Rats were microinjected 
with NSAIDs or saline for 5 days to induce tolerance. The distance from the 
bregma is −9.16 mm (A), −9.68 (B), and −9.8 (C), respectively.
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day antinociception was maximal for each drugs for ketorolac 
(t = 15.172, P < 0.001), for xefocam (t = 13.047, P < 0.001), for 
analgin (t = 10.135, P < 0.001), and clodifen (t = 9.432, P < 0.001) 
respectively (Figure 2B). However, subsequent NSAIDs microinjec-
tions caused progressively less antinociception, so by day 5 there 
was no effect, i.e., we observed a similar effect to the vehicle control 
of saline microinjections for both the TF (Figure 2A) and the HP 
(Figure 2B) tests, except analgin in TF latency. The latter did not 
show complete tolerance even at the fifth experimental day (t = 5.2, 
P < 0.05; Figure 2A).
opioid sensitivity
Control experiments
Control experiments with saline microinjections into the NRM 
followed by the μ-opioid antagonist naloxone statistically did not 
change the latency to respond in the TF and HP tests for the first 
and second experimental days (P > 0.05; Figures 3A,B).
tolerance to nsaids
Our investigation showed that microinjection of NSAIDs into 
the NRM produced antinociception as revealed by a latency 
increase in TF and HP responses compared to the saline control 
microinjected into the same nucleus. The TF latency significantly 
increased for analgin [ANOVA: F(5,44) = 53.797, (P < 0.0001)], 
clodifen [ANOVA: F(5,39) = 43.233, (P < 0.0001)], ketorolac 
[ANOVA: F(5,44) = 39.952, (P < 0.0001)], and xefocam [ANOVA: 
F(5,39) = 41.904, (P < 0.0001)]. On the first experimental day, 
the differences between treated and control groups were signifi-
cant for analgin (t = 11.854, P < 0.001), for xefocam (t = 11.096, 
P < 0.001), for ketorolac (t = 9.652, P < 0.001), and clodifen 
(t = 8.813, P < 0.001) respectively (Figure 2A).
We revealed similar significant differences in the HP laten-
cies for analgin [ANOVA: F(5,44) = 79.984, (P < 0.0001)], 
clodifen [ANOVA: F(5,39) = 33.024, (P < 0.0001)], ketorolac 
[ANOVA: F(5,44) = 68.839, (P < 0.0001)], and xefocam [ANOVA: 
F(5,39) = 67.945, (P < 0.0001)] respectively. On the first  treatment 
Figure 2 | Microinjections of NSAiDs into the NrM for five consecutive 
days result in progressively decrease in TF (A) and HP (B) latencies as 
compared to vehicle saline control (*P < 0.05, **P < 0.01, ***P < 0.001).
Figure 3 | Control experiments of post-treatment with naloxone after 
microinjections of saline into NrM does not significantly change TF (A) 
and HP (B) latencies either for the first or second days. N = 4 per group.
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analgin, clodifen, ketorolac, and xefocam induce tolerance, and 
also by mechanisms strongly related to the PAG (Tortorici and 
Vanegas, 2000; Tortorici et al., 2004, 2009). It has been shown 
that other non-opioid analgesics, e.g., aspirin also induce toler-
ance after repeated microinjections into the PAG (Vanegas and 
Tortorici, 2002; Pernia-Andrade et al., 2004). The PAG and its 
descending projections to the NRM are principal components of 
the descending antinociceptive pain-control system (Fields et al., 
2006; Henricher and Ingram, 2009; Heinricher et al., 2009; Ren 
and Dubner, 2009). In naive rats, microinjection of morphine and 
dipyrone into the PAG decrease the activity of pain-facilitating 
“on-cells” and increase the activity of pain inhibiting “off-cells” 
thus giving rise to antinociception (Tortorici et al., 2001, 2009; 
Fields, 2004).
Although similar effects of antinociception can be produced by 
direct action of morphine upon the RVM (Henricher et al., 1992), 
tolerance to morphine was not remarkably obtained by repeated 
microinjection into the RVM (Morgan et al., 2005). Furthermore, 
inactivation of the RVM did not prevent the development of toler-
ance to repeated morphine microinjections into the PAG, and toler-
Opioid sensitivity of NSAIDs
To examine in detail an opioid sensitivity of NSAIDs action we 
tested whether post-treatment with the μ-opioid antagonist 
naloxone into the NRM diminishes NSAID-induced antinocic-
eption on the first and second experimental days. Twenty minutes 
after NSAIDs testing, microinjection of naloxone into the NRM 
significantly decreased antinociceptive effects of NSAIDs on the 
first day in the TF for analgin (t = 5.432, P < 0.05), clodifen 
(t = 6.258, P < 0.01), ketorolac (t = 10.847, P < 0.001), and xefocam 
(t = 8.709, P < 0.001), respectively (Figure 4). The same effects 
we discovered in the HP test for analgin (t = 5.701, P < 0.05), 
clodifen (t = 5.287, P < 0.05), ketorolac (t = 7.303, P < 0.001), 
and xefocam (t = 5.64, P < 0.05), respectively (Figure 5). On the 
second day, naloxone showed trend effects in both TF and HP 
tests (Figures 4 and 5).
discussion
The obtained data revealed for the first time non-opioid tolerance 
to NSAIDs in the NRM. These results add evidence to the hypoth-
esis that, like opioids, non-opioid analgesics, particularly NSAIDs 
Figure 4 | experiments of post treatment with naloxone after microinjection of NSAiDs into NrM results in a significant decrease in TF latency for the first 
day for analgin (A), clodifen (B), ketorolac (C), and xefocam (D), respectively. On the second day, there are trend effects for all four non-opioid analgesics. N=4 per 
group. Here and in the next figure *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 5 | experiments of post treatment with naloxone after microinjection of NSAiDs into NrM results in a significant decrease in HP latency for the 
first day for analgin (A), clodifen (B), ketorolac (C), and xefocam (D), respectively. On the second day, there are trend effects for all four non-opioid analgesics. 
N=4 per group.
ance to systemic morphine did not develop if opioid receptors were 
blocked in the PAG even if the RVM remained intact (Lane et al., 
2005). The PAG is thus crucial for tolerance to morphine as well as 
non-opioid NSAIDs such as metamizol, clodifen, ketorolac, aspirin, 
and xefocam (Vanegas and Tortorici, 2002; Tortorici et al., 2003, 2004, 
2009). On the other hand, however, in this study we revealed for the 
first time tolerance induction to NSAIDs microinjected into NRM.
The mechanism producing tolerance to NSAIDs can be due to 
the participation of endogenous opioids, endorphins (Hernández-
Delgadillo and Cruz, 2006; Tsiklauri et al., 2006; Henricher and 
Ingram, 2009; Vanegas et al., 2010). Herein we clearly showed that 
the μ-opioid antagonist naloxone diminishes NSAID-induced 
antinociception on the first and second experimental days and 
impedes the development of tolerance to the antinociceptive effect 
of NSAIDs. Our findings affirm the results of other investigators 
that microinjection of dipyrone and aspirin, and systemic dipyrone 
are abolished by systemically injected and/or microinjections of 
the selective μ-opioid antagonists, naloxone, and CTOP (D-phe-
Cys-Tyr-D-trp-Orn-thr-Pen-thr-NH
2
; Pernia-Andrade et al., 2004; 
Hernández-Delgadillo and Cruz, 2006; Tortorici et al., 2009). The 
latter is a cyclic analog of the neuropeptide somatostatin and is 
known to block the analgesic effect of morphine (Tortorici et al., 
2009). Moreover, endogenous opioids are involved in the poten-
tiation of analgesia observed with the combination of morphine 
plus dipyrone (metamizol). The release of endogenous opioids by 
dipyrone could enhance exogenous opiate effects, explaining the 
need for the need for more naloxone to counteract the antinocicep-
tion produced by morphine plus dipyrone (Hernández-Delgadillo 
and Cruz, 2006).
The mechanisms whereby NSAIDs, in general, engage endog-
enous opioids are not completely understood. There is a proposed 
model for the PAG where γ-amino-butyric acid (GABA) containing 
synapses act as the plausible site where NSAIDs could converge 
with endogenous opioids. The PAG output neurons that drive 
antinociception via downstream relays, like the NRM and RVM, 
are tonically inhibited by local GABA-ergic synapses (Henricher 
and Ingram, 2009; Vanegas et al., 2010). Endogenous opioids reduce 
presynaptic release of GABA in the PAG. Furthermore, activation 
of μ-opioid receptors in the PAG brings about an elevation of the 
intracellular concentration of arachidonic acid metabolites. One of 
the pathways leads to the formation of hepoxolins, which increase 
potassium conductance. This is turn hyperpolarizes the presynaptic 
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RVM on-cells, thus leading to antinociception (analgesia). When 
tolerance develops, PAG microinjections of morphine (Tortorici 
et al., 2001), or metamizol (Tortorici et al., 2009) are no longer 
capable of affecting RVM neurons and inducing analgesia. These 
results show further neuronal relationships between opioid and 
non-opioid analgesics as regards the descending pain-control and 
modulation system (Vanegas et al., 2010).
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GABA-ergic terminals and decreases GABA release (Vaugan, 1998). 
Disinhibition of PAG output neurons would thus increase and drive 
antinociception in the downstream loop of the PAG–RVM–spinal 
dorsal horn (Wessendorf et al., 2006; Morgan et al., 2008). For this 
pathway to function, however, an activation of μ-opioid receptors 
seems to be necessary, because naloxone or CTOP block the effect 
of PAG-microinjected metamizol or aspirin (Pernia-Andrade et al., 
2004; Tortorici et al., 2009).
As mentioned above, the action of either opioid or non-opioid 
analgesics in the PAG leads to an excitation of PAG output neurons 
and this causes an activation of RVM off-cells and an inhibition of 
